Background With the advent of targeted therapies in ovarian cancer (OC), there is an impetus to identify patients with a BRCA1/2 mutation. Germline testing has already been integrated into the oncology setting using a mainstreamed model (MGT). Tumour testing is now available to detect the presence of somatic BRCA1/2 mutations. Aim To explore the introduction of mainstreamed BRCA1/2 tumour testing (MTT) in OC, focusing on clinical outcomes and patient experience. Methods A case study approach, using different research methods, was taken to gain an in depth understanding of the case (MTT) within its context. Results A service evaluation of the current state of MGT at UCLH found that in the 122 patients who were tested over 12 months, germline...
One of the most significant risk factors for the development of ovarian cancer (OC) is a genetic mut...
The presence of a germline BRCA1/2 mutation improves options for tailored risk-reducing strategies a...
BACKGROUND: Over recent years genetic testing for germline mutations in BRCA1/BRCA2 has become more ...
Objective: Pathogenic BRCA variants account for between 5.8-24.8% of ovarian cancers. The identifica...
The final publication is available at Springer via http://dx.doi.org/10.1007/s10897-017-0108-5Decrea...
Advances in DNA sequencing have made genetic testing fast and affordable, but limitations of testing...
The aim of this audit was to evaluate the usefulness and serviceability of testing for pathogenic mu...
Decreasing costs of genetic testing and advances in treatment for women with cancer with germline $\...
Genetic testing for germline-BRCA1/BRCA2 mutations in epithelial ovarian cancer (EOC) was commission...
Advances in DNA sequencing have made genetic testing fast and affordable, but limitations of testing...
Objective To determine the frequency of germline and somatic pathogenic BRCA1 and BRCA2 variants in...
Objective To determine the frequency of germline and somatic pathogenic BRCA1 and BRCA2 variants in...
Objective To determine the frequency of germline and somatic pathogenic BRCA1 and BRCA2 variants in...
Objective To determine the frequency of germline and somatic pathogenic BRCA1 and BRCA2 variants in...
Objective To determine the frequency of germline and somatic pathogenic BRCA1 and BRCA2 variants in...
One of the most significant risk factors for the development of ovarian cancer (OC) is a genetic mut...
The presence of a germline BRCA1/2 mutation improves options for tailored risk-reducing strategies a...
BACKGROUND: Over recent years genetic testing for germline mutations in BRCA1/BRCA2 has become more ...
Objective: Pathogenic BRCA variants account for between 5.8-24.8% of ovarian cancers. The identifica...
The final publication is available at Springer via http://dx.doi.org/10.1007/s10897-017-0108-5Decrea...
Advances in DNA sequencing have made genetic testing fast and affordable, but limitations of testing...
The aim of this audit was to evaluate the usefulness and serviceability of testing for pathogenic mu...
Decreasing costs of genetic testing and advances in treatment for women with cancer with germline $\...
Genetic testing for germline-BRCA1/BRCA2 mutations in epithelial ovarian cancer (EOC) was commission...
Advances in DNA sequencing have made genetic testing fast and affordable, but limitations of testing...
Objective To determine the frequency of germline and somatic pathogenic BRCA1 and BRCA2 variants in...
Objective To determine the frequency of germline and somatic pathogenic BRCA1 and BRCA2 variants in...
Objective To determine the frequency of germline and somatic pathogenic BRCA1 and BRCA2 variants in...
Objective To determine the frequency of germline and somatic pathogenic BRCA1 and BRCA2 variants in...
Objective To determine the frequency of germline and somatic pathogenic BRCA1 and BRCA2 variants in...
One of the most significant risk factors for the development of ovarian cancer (OC) is a genetic mut...
The presence of a germline BRCA1/2 mutation improves options for tailored risk-reducing strategies a...
BACKGROUND: Over recent years genetic testing for germline mutations in BRCA1/BRCA2 has become more ...